CRB-701 Shows Robust Efficacy in Oropharyngeal, Cervical Cancers; Data to be Presented at ASCO
Summary
Corbus Pharmaceuticals announced updated positive Phase 1/2 clinical data for its lead oncology drug, CRB-701, demonstrating robust activity in second-line oropharyngeal and cervical cancers. The data showed confirmed objective response rates (cORR) up to 42.9% in OPSCC and 34.4% in cervical cancer, alongside a favorable safety profile. This strong efficacy data for a Nectin-4 targeted ADC follows the FDA's Fast Track designation for CRB-701 in HNSCC in March and broad alignment with the FDA on its registration path in April. These results significantly de-risk the program and enhance its commercial prospects. The full data will be presented at the upcoming ASCO Annual Meeting from May 29 to June 2.
At the time of this announcement, CRBP was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.3M. The 52-week trading range was $6.72 to $20.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.